Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study

We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut and liver 2012, 6(1), , pp.98-106
Hauptverfasser: Park, Sang Hoon, Park, Choong Kee, Lee, Jin Woo, Kim, Young Seok, Jeong, Sook-Hyang, Kim, Yun Soo, Kim, Ju Hyun, Hwang, Seong Gyu, Rim, Kyu Sung, Yim, Hyung Joon, Cheong, Jae Youn, Cho, Sung Won, Lee, June Sung, Park, Young Min, Jang, Jeong Won, Lee, Chun Kyon, Shon, Joo Hyun, Yang, Jin Mo, Ju, Young Soo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea. Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was ≥6×10(5) IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p
ISSN:1976-2283
2005-1212
DOI:10.5009/gnl.2012.6.1.98